
    
      This is a single-center, double-blind, randomized, Phase 1 study to assess the safety and
      tolerability of HBV-001 D1 in healthy adult subjects. This will be an upward titration of two
      dose levels of HBV-001 D1 (10 µg and 50 µg of DEN1-80E) in 16 subjects across two cohorts.
      Participants in each cohort will receive HBV-001 D1 vaccine or placebo on Visits 1, 3 and 5.
    
  